Salmeterol Xinafoate clinical trials
Also written Salmeterol and Serevent.
Counted the way a researcher would: Salmeterol Xinafoate with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Salmeterol Xinafoate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Salmeterol Xinafoate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 4 Feb 1994 · SEREVENT · NDA 020236 (FDA, Drugs@FDA)
- European Union
- 18 Aug 2016 · Aerivio Spiromax · EMEA/H/C/002752 (EMA; in a combination; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
98 studies that test it; most in 2007 (11)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2002 | 2 |
| 2003 | 8 |
| 2004 | 10 |
| 2005 | 10 |
| 2006 | 9 |
| 2007 | 11 |
| 2008 | 7 |
| 2009 | 9 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 7 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 65 · Other 34
GlaxoSmithKline (37) · Boehringer Ingelheim (12) · Teva Branded Pharmaceutical Products R&D, Inc. (4) · University of Dundee (3) · Milton S. Hershey Medical Center (2) · University of Copenhagen (2) · Intech Biopharm Ltd. (2) · University of Miami (2)
Often tested with
Tested in the same studies.
Fluticasone (56) · Tiotropium (17) · Montelukast (7) · Formoterol (5) · Budesonide (3) · Albuterol (3) · Indacaterol (2) · Therapeutic Procedure (1)
Related medicines
As reviewed, each with the page that says it.
- One of Bronchodilators source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Salmeterol Xinafoate.
- Dec 2026Salmeterol Effect on Exercise PerformanceNot applicable · University of Copenhagen
Studies
Open first, then newest update. How each study uses Salmeterol Xinafoate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 99
- Salmeterol Effect on Exercise PerformanceRecruitingNot applicableUniversity of CopenhagenNCT06655012Written as SalmeterolHow we know
- Tiotropium/Salmeterol Inhalation Powder in COPDTerminatedPhase 3Boehringer IngelheimNCT00668772Written as Tiotropium/SalmeterolHow we know
- Sub-Sensitivity to Long-Acting Bronchodilators (LABA)CompletedNot applicableNational Jewish HealthNCT01117116Written as fluticasone propionate and salmeterolHow we know
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with AsthmaCompletedPhase 3Eurofarma Laboratorios S.A.NCT01202097Written as Salmeterol/FluticasoneHow we know
- A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.CompletedPhase 3Boehringer IngelheimNCT00274560Written as SalmeterolHow we know
- Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in AsthmaStatus unknownPhase 4Imperial College LondonNCT04503460Written as Salmeterol XinafoateHow we know
- A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With AsthmaCompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT04677959Written as Fluticasone propionate/salmeterol (FS)How we know
- Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPDCompletedPhase 3Boehringer IngelheimNCT00662792Written as Tiotropium/Salmeterol (T+S_PE)How we know
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone PropionateCompletedPhase 1Kindeva Drug DeliveryNCT02232087Written as SalmeterolHow we know
- Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)CompletedPhase 3Organon and CoNCT00245570Written as Comparator: SalmeterolHow we know
- Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and OlderCompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT02437604Written as Treatment B: FS MDPIHow we know
- Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder InhalerCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02980133Written as Fluticasone Propionate/SalmeterolHow we know
- A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With AsthmaCompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT02680561Written as Fluticasone propionate/salmeterolHow we know
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03034915Written as Salmeterol 50 mcg via DISKUSHow we know
- Generation of Biological Samples Positive to Salmeterol for Anti-Doping ControlCompletedPhase 1Parc de Salut MarNCT04195867Written as Salmeterol XinafoateHow we know
- Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)CompletedNot applicableWest-Ward PharmaceuticalNCT03535870Written as Fluticasone propionate/salmeterolHow we know
- Fluticasone and Salmeterol in Allergic RhinitisCompletedPhase 4University of DundeeNCT01388595Written as SalmeterolHow we know
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting BronchodilatorCompletedPhase 4Novartis PharmaceuticalsNCT01794780Written as LABA/ICS based treatment: salmeterol/fluticasoneHow we know
- Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate AsthmaCompletedPhase 4University of DundeeNCT00830505Written as fluticasone/salmeterolHow we know
- A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or ExerciseCompletedPhase 4GlaxoSmithKlineNCT00118716Written as Fluticasone propionate/salmeterolHow we know
See all 99 studies that test Salmeterol Xinafoate →
Given beside what is tested · 17 — Salmeterol Xinafoate is usual care or a partner of the new treatment
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.RecruitingPhase 3Novartis PharmaceuticalsNCT05776927Written as Salmeterol Xinafoate / Fluticasone PropionateHow we know
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaActive, not recruitingPhase 2SanofiNCT06676319Written as Fluticasone/SalmeterolHow we know
- Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)CompletedPhase 3Organon and CoNCT00127166Written as Salmeterol xinafoateHow we know
- Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With AsthmaCompletedPhase 2SanofiNCT02573233Written as fluticasone propionate and salmeterolHow we know
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled AsthmaCompletedPhase 3GlaxoSmithKlineNCT02924688Written as Fluticasone/salmeterol (FSC)How we know
- Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe AsthmaCompletedPhase 2GlaxoSmithKlineNCT03207243Written as Fluticasone propionate/salmeterolHow we know
- Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)CompletedPhase 3Milton S. Hershey Medical CenterNCT00565266Written as salmeterol xinafoateHow we know
- GSK159802 In Healthy Male Subjects And AsthmaticsCompletedPhase 1GlaxoSmithKlineNCT00364273Written as SalmeterolHow we know
- Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic AsthmaCompletedPhase 2SanofiNCT01312961Written as Fluticasone/Salmeterol combination therapyHow we know
- Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPDCompletedPhase 4Novartis PharmaceuticalsNCT02055352Written as SalmeterolHow we know
- Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPDCompletedPhase 2Boehringer IngelheimNCT00535366Written as SalmeterolHow we know
- Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent AsthmaCompletedPhase 2NovartisNCT00557440Written as fluticasone propionate/salmeterolHow we know
- Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®CompletedPhase 2AstraZenecaNCT01048333Written as SalmeterolHow we know
- Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3NovartisNCT00669617Written as Salmeterol/fluticasone (50/500 μg)How we know
- A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Novartis PharmaceuticalsNCT00622635Written as Salmeterol 50 μgHow we know
- Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3NovartisNCT00615030Written as SalmeterolHow we know
- Dose Ranging Study for Indacaterol in Japanese Asthma PatientsCompletedPhase 2Novartis PharmaceuticalsNCT00403754Written as SalmeterolHow we know
As the comparator · 58 — what is tested is compared with Salmeterol Xinafoate
- Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)TerminatedPhase 3Boehringer IngelheimNCT00662740Written as SalmeterolHow we know
- ANTES B+ Clinical TrialTerminatedPhase 4Fundacio Privada Mon Clinic BarcelonaNCT06282861Written as SereventHow we know
- Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly GenotypesCompletedNot applicableColumbia UniversityNCT00521222Written as Fluticasone with salmeterolHow we know
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumCompletedPhase 3Novartis PharmaceuticalsNCT03158311Written as Salmeterol/fluticasone plus tiotropiumHow we know
- Uncontrolled Lower Respiratory Symptoms in the WTC Survivor ProgramCompletedNot applicableNYU Langone HealthNCT02024204Written as Salmeterol 21mcg for 3 MonthsHow we know
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT02571777Written as salmeterol/fluticasoneHow we know
- The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the DiskusCompletedPhase 4Boehringer IngelheimNCT03240575Written as SalmeterolHow we know
- A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT02554786Written as Salmeterol xinafoate/fluticasone propionateHow we know
- Cardiovascular Function in COPD PatientsCompletedPhase 4Boehringer IngelheimNCT03055988Written as SalmeterolHow we know
- Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDCompletedPhase 4Novartis PharmaceuticalsNCT02603393Written as Salmeterol/fluticasoneHow we know
- Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 YearsStatus unknownPhase 3Mundipharma (China) Pharmaceutical Co. LtdNCT03387241Written as fluticasone/ salmeterolHow we know
- Effects of Particle Size in Small Airways DysfunctionCompletedPhase 4University of DundeeNCT01892787Written as SalmeterolHow we know
- A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedPhase 2PfizerNCT00808288Written as SalmeterolHow we know
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaCompletedPhase 3GlaxoSmithKlineNCT02446418Written as SalmeterolHow we know
- Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Boehringer IngelheimNCT02172794Written as SalmeterolHow we know
- Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/SalmeterolTerminatedPhase 4Mundipharma Korea LtdNCT02491970Written as Fluticasone/SalmeterolHow we know
- Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)CompletedPhase 3Brigham and Women's HospitalNCT01290874Written as SalmeterolHow we know
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT01817764Written as Fluticasone propionate/salmeterolHow we know
- Repeat Doses Of A New Medication (GW642444) In Asthmatic PatientsCompletedPhase 2GlaxoSmithKlineNCT00347139Written as Salmeterol 50mcgHow we know
- A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT01822899Written as Fluticasone propionate/SalmeterolHow we know
Showing 20 of 58.
Codes
What other systems call Salmeterol Xinafoate · ClinicalTrials.gg INT006509
- MeSH (NLM) D000068299Salmeterol XinafoateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6EW8Q962A5SALMETEROL XINAFOATEConfirmed FDA, NLM, Wikidata
- RxNorm 72616Confirmed FDA, Wikidata
- Wikidata Q27264747salmeterol xinafoateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61935Salmeterol XinafoateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068299 | Salmeterol Xinafoate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6EW8Q962A5 | SALMETEROL XINAFOATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 72616 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27264747 | salmeterol xinafoate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61935 | Salmeterol Xinafoate | One source FDA |
Also registered as salmeterol (UNII 2I4BC502BT · RxNorm 36117).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.